Celgene Corporation (CELG) Shares Sold by Chase Investment Counsel Corp
Chase Investment Counsel Corp cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,877 shares of the biopharmaceutical company’s stock after selling 2,069 shares during the period. Celgene Corporation makes up approximately 2.8% of Chase Investment Counsel Corp’s investment portfolio, making the stock its 10th largest position. Chase Investment Counsel Corp’s holdings in Celgene Corporation were worth $5,698,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in CELG. Motco raised its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter valued at $118,000. Oakworth Capital Inc. raised its position in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Acropolis Investment Management LLC purchased a new stake in shares of Celgene Corporation during the second quarter valued at approximately $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the last quarter. Institutional investors and hedge funds own 78.34% of the company’s stock.
Celgene Corporation (NASDAQ CELG) traded down 0.28% during trading on Friday, reaching $129.68. 2,313,034 shares of the company were exchanged. The firm’s 50 day moving average price is $133.39 and its 200-day moving average price is $125.39. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The stock has a market capitalization of $101.46 billion, a price-to-earnings ratio of 40.16 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share. On average, equities research analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.
CELG has been the subject of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $138.00 target price on shares of Celgene Corporation in a research note on Monday, May 1st. Argus downgraded shares of Celgene Corporation from a “buy” rating to a “hold” rating and upped their target price for the company from $123.91 to $124.46 in a research note on Friday, May 5th. They noted that the move was a valuation call. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $136.87 target price for the company in a research note on Monday, May 8th. Jefferies Group LLC set a $154.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Saturday, May 13th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $98.00 target price (up previously from $93.00) on shares of Celgene Corporation in a research note on Wednesday, May 17th. One analyst has rated the stock with a sell rating, six have given a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $147.44.
In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. Insiders have sold 253,761 shares of company stock worth $33,792,445 over the last ninety days. Insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.